Please login to the form below

Not currently logged in
Email:
Password:

Zealand Pharma

This page shows the latest Zealand Pharma news and features for those working in and with pharma, biotech and healthcare.

Boehringer bolsters NASH pipeline with $870m Yuhan deal

Boehringer bolsters NASH pipeline with $870m Yuhan deal

therapies. Boehringer is a diabetes specialist and already has a dual GLP-1 and glucagon agonist, partnered with Zealand Pharma, in phase 1b testing. ... later this year, as well as a drug candidates for the disease covered by its recently expanded $201m

Latest news

More from news
Approximately 1 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Acquisition. $244m. Zealand/. Royalty Pharma. Royalty streams and milestones for Soliqua 100/33/. ... So two opportunities here – acquisition of animal health products and out-licensing to Bayer’s pharma business.

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    For an indepth analysis of these deals, read'Pharma deals during July 2014'. ... 635. Zealand Pharma/ Boehringer Ingelheim. R&D collaboration. Peptide discovery collaboration with cardio-metabolic focus.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • David Horn Solomon takes the helm of Akari Therapeutics David Horn Solomon takes the helm of Akari Therapeutics

    David has a strong track record of leading phase II stage companies like Akari, most notably at Zealand Pharma where he led the development of lixisenatide, which is now commercialised by ... Sanofi.”. His other roles have included CEO at Bionor Pharma

  • Glythera appoints Dr Mike Owen Glythera appoints Dr Mike Owen

    Owen is also currently a director of Avacata plc, Blink Biomedical SAS, GammDelta Therapeutics, Ossianix Inc, ReNeuron plc and Zealand Pharma A/S. ... pipeline and building strategic partnerships with large pharma.”.

  • Bionor names executive management team additions Bionor names executive management team additions

    He has extensive experience as head of operation in public and private research intensive organisations and most recently served as director and general counsel to the management at Zealand Pharma. ... Rolstead has over 15 years of experience and has

  • Zealand announces management changes Zealand announces management changes

    Zealand Pharma is set to make a series of restructuring changes that will shake-up a number of positions at the firm.  . ... The R&D arm of Zealand will be split into two parts, each with direct representation in management, while investor relations and

  • Zealand's Arvind Hundal steps down as chief business officer Zealand's Arvind Hundal steps down as chief business officer

    She leaves after five years with the Danish biotech company. Dr Arvind Hundal has left Danish biotech company Zealand Pharma to pursue other opportunities.  . ... served as a member of AstraZeneca's strategic planning business development organisation

More from appointments
Approximately 5 fully matching, plus 4 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics